Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| BRWEP2024W014030105 | Other Grant/Funding Number | Beijing Research Ward Excellence Program, BRWEP |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Permanent pacemaker implantation is traditionally performed under fluoroscopic (X-ray) guidance. Although effective, fluoroscopy exposes patients and medical staff to ionizing radiation. Transthoracic echocardiography (TTE) is a non-invasive ultrasound imaging technique that allows real-time visualization of cardiac structures without radiation exposure. However, its role in guiding permanent pacemaker implantation has not been systematically evaluated.
This study aims to assess the feasibility and safety of performing permanent pacemaker implantation under sole TTE guidance. In the first phase, eligible patients will undergo pacemaker implantation guided only by transthoracic echocardiography. In the second phase, outcomes of patients treated with TTE guidance will be compared with matched patients undergoing conventional fluoroscopy-guided implantation. The study will evaluate procedural success, lead positioning accuracy, electrical performance, complication rates, and elimination of radiation exposure. The overall goal is to determine whether a radiation-free imaging strategy can safely replace conventional fluoroscopic guidance in selected patients requiring pacemaker implantation.
Fluoroscopy-guided permanent pacemaker implantation has been the standard imaging strategy for decades. While fluoroscopy provides reliable projection-based visualization of lead advancement, it exposes patients and medical personnel to ionizing radiation and does not allow direct visualization of myocardial tissue contact or early structural complications. Increasing awareness of cumulative radiation exposure has led to the exploration of alternative imaging strategies in structural and electrophysiological interventions.
Transthoracic echocardiography (TTE) provides real-time, radiation-free visualization of cardiac chambers, septal structures, valvular anatomy, and the pericardial space. TTE has been successfully applied in selected structural heart procedures; however, its use in guiding permanent pacemaker implantation has not been systematically studied. The principal challenges of TTE-guided pacing include limited visualization of the entire lead shaft, difficulty in assessing three-dimensional orientation, and uncertainty regarding fixation mechanics. With procedural refinements and structured imaging protocols, these limitations may be overcome.
This study is designed to evaluate a radiation-free implantation strategy using sole transthoracic echocardiographic guidance. The first component prospectively assesses procedural feasibility and safety in consecutively enrolled patients. The second component compares outcomes of the TTE-guided cohort with a matched cohort undergoing conventional fluoroscopy-guided implantation. The same prospectively enrolled TTE cohort will serve both feasibility assessment and comparative analysis.
The central hypothesis is that TTE-guided pacemaker implantation can achieve high procedural success and acceptable electrical performance while eliminating radiation exposure and maintaining safety comparable to conventional fluoroscopic guidance. By leveraging direct septal visualization and continuous structural monitoring, this approach may provide mechanistic advantages in lead positioning accuracy and complication detection.
If validated, this strategy could represent an important step toward fully radiation-free electrophysiological and structural cardiac interventions.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TTE-guided arm | Experimental | Transthoracic Echocardiography-Guided Pacemaker Implantation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Permanent Pacemaker Implantation | Procedure | Permanent pacemaker implantation performed under sole transthoracic echocardiographic (TTE) guidance without the use of fluoroscopy. Venous access, lead advancement, positioning, and fixation are guided by real-time transthoracic imaging. Ventricular leads are positioned at the interventricular septum under direct echocardiographic visualization. In dual-chamber systems, atrial leads are positioned at the atrial septum due to limitations in visualizing the right atrial appendage under transthoracic imaging. Lead position, septal contact, and potential procedural complications (e.g., pericardial effusion, valvular interference) are continuously assessed using multi-plane echocardiographic views. Fluoroscopy is reserved only for bailout situations if adequate lead positioning cannot be achieved under TTE guidance. |
| Measure | Description | Time Frame |
|---|---|---|
| Procedural Feasibility and Success Rate | Feasibility phase: Successful completion of permanent pacemaker implantation under sole transthoracic echocardiographic (TTE) guidance without fluoroscopic conversion and with acceptable acute electrical parameters (capture threshold ≤1.5 V at 0.4 ms, stable sensing amplitude, and lead impedance within manufacturer-recommended range). Comparative phase: Successful device implantation without major procedural complications and with acceptable acute electrical parameters. | From initiation of vascular access to hospital discharge, assessed up to 5 days after the index procedure. |
| Measure | Description | Time Frame |
|---|---|---|
| Total Procedure Time | Total procedure time measured from skin preparation to wound dressing completion. | During the index procedure (single-day assessment at Day 0). |
| Lead Positioning Time | Time required to achieve stable ventricular septal lead positioning and atrial septal lead positioning under imaging guidance. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Xiangbin Pan, MD, PhD | National Center for Cardiovascular Disease, China & Fuwai Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences | Beijing | 100037 | China |
Individual participant data (IPD) will not be shared due to institutional data protection policies and the relatively small sample size, which may increase the risk of participant re-identification. De-identified aggregate data will be reported in peer-reviewed publications.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| During the index procedure (single-day assessment at Day 0). |
| Radiation Exposure | Total fluoroscopy time (minutes) and cumulative radiation dose (mGy). For the TTE-guided group, fluoroscopy time is expected to be zero unless bailout conversion is required. | During the index procedure (single-day assessment at Day 0). |
| Acute Electrical Performance | Atrial and ventricular pacing thresholds, sensing amplitude, and lead impedance measured at implantation. | Immediately post-implantation (Day 0, within 24 hours after device placement). |
| Electrical Stability at 3 Months | Maintenance of acceptable pacing thresholds and absence of lead dislodgement. | Assessed at 3 months (±14 days) after implantation. |
| Major Procedural Complications | Composite of cardiac perforation, pericardial tamponade, pneumothorax, major vascular injury, pocket hematoma requiring intervention, device infection, or procedure-related mortality. | From the date of the index procedure until the first occurrence of a major procedural complication or completion of 12-month follow-up, whichever occurs first. |
| Structural Cardiac Impact | New pericardial effusion or significant progression of tricuspid regurgitation assessed by transthoracic echocardiography. | Assessed at discharge (≤5 days), 3 months (±14 days), 6 months (±30 days), and 12 months (±30 days) after implantation. |